OpenAlex
PricingAboutJobs
Log inGet started
Work

The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation

HTML

Year: 2014
Type: article
Source: Molecular Cancer Therapeutics
DOI: 10.1158/1535-7163.mct-14-0257
Authors: Vipin Yadav, Teresa F. Burke, Lysiane Huber, Robert D. Van Horn, Youyan Zhang, Sean G. Buchanan, Edward M. Chan, James J. Starling, Richard P. Beckmann, Sheng-Bin Peng
Institution: Eli Lilly (United States)
Language: English

Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: vemurafenib resistance, CDK4/6 inhibition, acquired drug resistance, combination therapy, apoptosis, G1 cell cycle arrest
SDG: Good health and well-being

Open Access status: closed

Funder: Eli Lilly and Company
OpenAlex ID: W2166229764
FWCI: 4.728
Cites: 33
Cited by: 148
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security